Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (321-330 of 333) with videos related to

Pageof 34
Sort By:
The American Journal of Gastroenterology|March 14, 2024
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Journal of Hepatology|January 8, 2025
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)Edo J Dongelmans, Grishma Hirode, Bettina E Hansen, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2019
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionGraham S Cooke, Isabelle Andrieux-Meyer, Tanya L Applegate, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Respiratory Medicine|February 8, 2021
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trialJordan J Feld, Christopher Kandel, Mia J Biondi, et al.
Gastroenterology|August 3, 2019
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaAmit G Singal, Nicole E Rich, Neil Mehta, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|January 21, 2019
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyAmit G Singal, Nicole E Rich, Neil Mehta, et al.
Pageof 34

Showing results (321-330 of 333) with videos related to

Sort By:
Pageof 34
The American Journal of Gastroenterology|March 14, 2024
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Journal of Hepatology|January 8, 2025
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)Edo J Dongelmans, Grishma Hirode, Bettina E Hansen, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2019
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionGraham S Cooke, Isabelle Andrieux-Meyer, Tanya L Applegate, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Respiratory Medicine|February 8, 2021
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trialJordan J Feld, Christopher Kandel, Mia J Biondi, et al.
Gastroenterology|August 3, 2019
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaAmit G Singal, Nicole E Rich, Neil Mehta, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|January 21, 2019
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyAmit G Singal, Nicole E Rich, Neil Mehta, et al.
Pageof 34